Zacks Investment Research cut shares of Aphria (NYSE:APHA) from a hold rating to a sell rating in a research note released on Friday, Zacks.com reports.

According to Zacks, “Aphria Inc. produces, supplies and sells medical cannabis primarily in Canada. The company offers sativa, indica and hybrid medical marijuana products, as well as cannabis oils. Aphria Inc. is headquartered in Leamington, Canada. “

A number of other equities analysts have also recently issued reports on APHA. ValuEngine cut Aphria from a buy rating to a hold rating in a report on Monday, April 15th. Clarus Securities assumed coverage on Aphria in a report on Tuesday, April 16th. They set a buy rating and a $22.75 target price on the stock. Seaport Global Securities assumed coverage on Aphria in a report on Thursday, February 21st. They set a buy rating and a $18.00 target price on the stock. CIBC assumed coverage on Aphria in a report on Friday, January 18th. They set a neutral rating on the stock. Finally, Cormark set a $15.00 target price on Aphria and gave the stock a buy rating in a report on Saturday, February 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $15.69.

Shares of APHA opened at $7.86 on Friday. Aphria has a 1 year low of $3.75 and a 1 year high of $16.86. The stock has a market cap of $1.92 billion, a price-to-earnings ratio of 56.14 and a beta of 4.08.

A number of institutional investors and hedge funds have recently modified their holdings of APHA. ETF Managers Group LLC acquired a new stake in shares of Aphria during the fourth quarter worth about $15,389,000. Norges Bank acquired a new stake in shares of Aphria during the fourth quarter worth about $10,301,000. TD Asset Management Inc. acquired a new stake in shares of Aphria during the fourth quarter worth about $4,073,000. Bank of America Corp DE acquired a new stake in shares of Aphria during the fourth quarter worth about $2,175,000. Finally, Deutsche Bank AG acquired a new stake in shares of Aphria during the fourth quarter worth about $960,000. Hedge funds and other institutional investors own 10.39% of the company’s stock.

About Aphria

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

Featured Article: Risk Tolerance and Your Investment Decisions

Get a free copy of the Zacks research report on Aphria (APHA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aphria (NYSE:APHA)

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.